---
layout: post
title: "Pediatric Study Plans for Oncology Drugs: Questions and Answers; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:08 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-00592
original_published: 2020-01-16 00:00:00 +0000
significance: 8.00
---

# Pediatric Study Plans for Oncology Drugs: Questions and Answers; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 16, 2020 00:00 UTC
**Document Number:** 2020-00592

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Pediatric Study Plans for Oncology Drugs: Questions and Answers." This draft guidance provides information to sponsors regarding the submission of an initial pediatric study plan (iPSP), as required by the Federal Food, Drug, and Cosmetic Act (FD&C Act), for oncology drugs only. Specifically, when finalized, this draft guidance will provide FDA's current thinking regarding iPSPs for oncology drugs in light of the amendments to the FD&C Act made by the FDA Reauthorization Act of 2017 (FDARA). FDA has received a number of questions on this topic and, as a result, is providing this draft guidance in a question and answer format, addressing the most frequently asked questions.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/16/2020-00592/pediatric-study-plans-for-oncology-drugs-questions-and-answers-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2020-00592

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
